- 1 Title: Antibiotic prescribing patterns by age and sex in England: why we need to take this
- 2 variation into account to evaluate antibiotic stewardship and AMR selection
- 3 Naomi R Waterlow<sup>1,2</sup>, Tom Ashfield<sup>3</sup>, Gwenan M Knight<sup>1,2</sup>
- 4 1 - Centre for Mathematical Modelling of Infectious Diseases, Department of Infectious Disease
- 5 Epidemiology, London School of Hygiene and Tropical Medicine, WC1E 7HT
- 6 2 - AMR Centre, London School of Hygiene and Tropical Medicine, WC1E 7HT
- 7 3 - The Signpost, Winchester, England
- 8
- 9
- 10
- 11

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 12 Structured Abstract

- 13 Objectives
- 14 The drivers of antimicrobial resistance (AMR) likely vary substantially by different
- 15 demographics. However, few complete open national detailed data exist on how
- 16 antibiotic use (ABU) varies by both age and sex.
- 17 Methods
- 18 Here, prescriptions of antibiotics from General Practices in England for 2015-2023
- 19 disaggregated by 5-year age bands and sex were analysed at the national and Integrated
- 20 Care Board (ICB) level. From a total of 249,578,795 prescriptions (across 9 years), 63%
- 21 were given to women and the most prescribed were amoxicillin, nitrofurantoin and
- 22 flucloxacillin sodium. Prescriptions per 100K population varied substantially across sex,
- 23 age, geographical region, season, year, COVID-19 pandemic period and drug.
- 24 Results
- 25 Most antibiotics were prescribed more to women across most age bands (84% of
- 26 antibiotics had more prescriptions to females across 50% of age bands). We show how
- 27 this variation requires a more nuanced approach to comparing ABU across geographies
- and highlight that AWaRe targets are not met uniformly (young men have a higher
- 29 proportion of "Watch" antibiotic prescriptions). We also show the impact on ABU of
- 30 time-sensitive interruptions, including differential age-targeted influenza vaccination,
- 31 COVID-19 restrictions and a shortage of amoxicillin combined with a Streptococcus A
- 32 outbreak. Comparing to open access AMR data (MRSA in bloodstream infections)
- highlights the complexity of the link between ABU and AMR.

34 Conclusions

- 35 These detailed differences in ABU across England suggest that there should be large
- 36 variation in AMR burden by age and sex, which now need to be quantified with detailed
- 37 open access AMR data for a better intervention design.

# 38 Introduction

39	
40	The global public health priority that is antimicrobial resistance (AMR) is driven by a
41	population-specific combination of antibiotic selection and transmission. There are
42	many global targets that focus on the reduction of antibacterial use (ABU). One such
43	target already adopted by the WHO 13 $^{ m th}$ General Programme of Work is to have at least
44	60% of total antibiotic consumption within the Access group of AWaRe antibiotics $^{1-3}$ .
45	More ambitiously, it has been proposed that 80% or more of oral antibiotic use could be
46	Access <sup>2,4</sup> . To achieve such targets without affecting patient care, it will be key to
47	produce nuanced information about ABU across different subpopulations.
48	Most antibiotics are given outside of hospital settings <sup>5,6</sup> and previous studies have
49	suggested that primary care antibiotic use (and hence exposure) varies substantially by
50	age and by sex. A systematic review of primary care prescribing in 2016 suggested that
51	women in high income settings receive a significantly higher number of prescriptions,
52	particularly in the 16 to 54 years age band $^7$ . This is supported by sub-national
53	analyses <sup>8–10</sup> from the UK, for example approximately twice as many antibiotic
54	prescriptions given to women in 2013-2015, and 70% of all prescriptions after excluding
55	antibiotics used to treat urinary tract infections (UTIs) <sup>8</sup> . Antibiotic exposure rates are
56	often "hockey-stick" shaped across age, with high levels in young children and an
57	exponential increase with age <sup>7,11</sup> . This is likely to reflect that different age/sex sub-
58	groups present with different rates of infections $^{\rm 12}$ and hence some level of appropriate
59	prescription variation. For example women have higher rates of UTIs <sup>13</sup> .

60	Antibiotic use also varies geographically at national and sub-national levels <sup>14–16</sup> .
61	Identifying outliers once patient composition is accounted for, is vital for improving
62	antibiotic stewardship <sup>17,18</sup> . To do this, various measures have been proposed such as
63	the English STAR-PU $^{19}$ which uses different prescribing weights in different ages and
64	sexes. Issues with this metric include the lack of accounting of co-morbidities $^{18}$ and the
65	grouping of all antibiotics together masking variation in antibiotic use due to patient or
66	GP-related factors <sup>20</sup> , although variation in prescribing may be decreasing over time <sup>21</sup> .
67	To reduce ABU many age-specific interventions could be considered, for example
68	vaccination programmes are postulated to reduce both unnecessary and necessary
69	antibiotic use <sup>22,23</sup> . Evidence that such a reduction in antibiotic exposure leads to
70	reduced resistance is mixed $^{24}$ , but age- and sex-disaggregated ABU could be used to
71	reveal where there is a link between vaccination and ABU, as well as ABU and
72	resistance rates. However, few ecological open access ABU or AMR data exist
73	disaggregated by both age and sex. In one of the only detailed age and sex analyses, we
74	have previously shown that AMR prevalence in bloodstream infections in Europe varies
75	substantially by age, sex and bacteria-antibiotic combination <sup>25</sup> .
76	

Here we use 9 years of open access national data on antibiotic prescriptions from
primary care in England available at an unprecedented level of both age and sex
disaggregation to reveal the variation in ABU. We test assumptions about antibiotic
weightings used for identifying prescribing outliers, conduct a nuanced analysis of
AWaRe targets, generate estimates of the impact on ABU of age-based influenza
vaccination, and explore the link between ABU and AMR. The patterns we find show the

- importance of such nuanced data and emphasise the need for more disaggregated AMR 83
- 84 data.

# 85 Materials & Methods

86

87	The number of primary care antibiotic prescriptions by 23 age bands and 3 genders in
88	England & Wales was received through two freedom of information requests (FOI-
89	01671, FOI-01975) $^{26}$ to the NHS Business Service Authority (NHSBSA) Information
90	Services Data Warehouse containing information from the NHSBSA Prescription
91	Services. The first FOI contains data at General Practice (GP) and Integrated Care Board
92	(ICB) level for England and some of Wales. The second is total national English data
93	only.
94	
95	This data covers the 9 year period of April 2015 to December 2023 inclusive, by month,
96	and includes all medicines from the British National Formulary (BNF) section 5.1:
97	Antibacterial drugs <sup>27</sup> . Datapoints relating to fewer than 5 items prescribed were
98	redacted by NHSBSA for privacy reasons. The 23 age bands were "0-1", "2-5" and then
99	5yr age bands up to "105+". The three gender classes included were "Male", "Female"
100	and "Indeterminate" (where information does not confirm either Male or Female). We
101	used number of items prescribed in our analysis, so as to avoid double-counting of
102	patients <sup>26</sup> .
103	
104	Of total prescriptions in the dataset, 3.3% were prescribed to a patient of unknown
105	gender or age band. We excluded these prescriptions from our analysis, although note
106	that the frequency varied with time, with fewer unknowns over time (Appendix 1 section

107 2). We also excluded prescriptions given to individuals of "Indeterminate" gender, due

to the small numbers (6247 Items, 0.0024%) and the antibiotics for which there were

109	less than an average of 10 prescriptions per year (22 antibiotics, Appendix 1 section 3).
110	For our main analysis, we assumed all redacted numbers of items had a value 1 (from a
111	possible 1,2,3 or 4), and run sensitivity analyses on this number (Appendix 1 Section 7).
112	
113	Population sizes by age were obtained from the Office for National Statistics (ONS) and
114	mid-year estimates were used for each calendar year <sup>28,29</sup> (Appendix 1 Section 4). We
115	only included prescriptions for England in the analysis, and only those for 2023 were
116	used for sub-national analyses, due to changes in the definitions of the ICBs. Data from
117	NHSBSA provides "Gender", but most other sources use "Sex". We have assumed that
118	we can match these two in this analysis.
119	
120	We calculated an updated STAR-PU weighting of antibiotic prescriptions per age band
121	and sex, with smaller age bands $^{19}$ . The updated comparison metric (UCM) weightings
122	were calculated using females aged 66-70 as baseline (a subset of the STAR-PU 65-74
123	female baseline). Our UCM weightings were then applied to the ICBs in 2023, using the
124	same STAR-PU principles: the new UCM weightings were multiplied by the relevant
125	populations in each ICB, and the total prescriptions per UCM-population were used to
126	compare ICBs. In addition, drug family-based weightings were calculated using the
127	same methodology ("UCM-family"), but prescriptions from each drug family were used.
128	For children aged up to 16 (the only age groups where there were sometimes no
129	prescriptions) a value or 0.01 was used if there were no data in that age band, and limits
130	were set of 0.01 to 100.

Drugs were classified into the AWaRe categories using a World Health Organisation
reference table <sup>30</sup>. Where drug names were not identical, these were manually matched
(Appendix 1 section 1).

135

136	Age bands covered by influenza vaccination were extracted from the annual UKHSA
137	reports <sup>31</sup> , and these were compared to prescriptions of antibiotics used in respiratory
138	tract infections (RTIs)(defined as all drugs in the BNF categories "cephalosporins and
139	other beta-lactams" and "penicillins"), excluding amoxicillin. Amoxicillin was excluded
140	due to the very large number of prescriptions, and it's use in many varieties of infection
141	<sup>32</sup> . The influenza season was defined as 1st of October to 30th March inclusive. The
142	number of prescriptions given to patients in age bands that matched closely to the
143	vaccination groups was calculated where possible (0-1, 2-5, 5-10, 11-15, 50-65, 65+).
144	
145	We extracted the only publicly available data on AMR infection split by age and sex. This
145 146	We extracted the only publicly available data on AMR infection split by age and sex. This was for <i>Staphylococcus aureus</i> bloodstream infection data from UKHSA <sup>33</sup> . The
146	was for <i>Staphylococcus aureus</i> bloodstream infection data from UKHSA <sup>33</sup> . The
146 147	was for <i>Staphylococcus aureus</i> bloodstream infection data from UKHSA <sup>33</sup> . The proportion of these BSIs due to <i>S. aureus</i> that were methicillin-resistant (MRSA) were
146 147 148	was for <i>Staphylococcus aureus</i> bloodstream infection data from UKHSA <sup>33</sup> . The proportion of these BSIs due to <i>S. aureus</i> that were methicillin-resistant (MRSA) were compared to prescriptions of antibiotics in the BNF categories "cephalosporins and
146 147 148 149	was for <i>Staphylococcus aureus</i> bloodstream infection data from UKHSA <sup>33</sup> . The proportion of these BSIs due to <i>S. aureus</i> that were methicillin-resistant (MRSA) were compared to prescriptions of antibiotics in the BNF categories "cephalosporins and
146 147 148 149 150	was for <i>Staphylococcus aureus</i> bloodstream infection data from UKHSA <sup>33</sup> . The proportion of these BSIs due to <i>S. aureus</i> that were methicillin-resistant (MRSA) were compared to prescriptions of antibiotics in the BNF categories "cephalosporins and other beta-lactams" and "penicillins".

- 155 All code is available on github (https://github.com/NaomiWaterlow/prescription\_foi)
- 156 and was conducted in R  $^{34}$ .
- 157
- 158 Sensitivity analysis
- 159 The main issue to explore in the data was the uncertainty in the redacted small numbers
- 160 ("\*") when the number of prescriptions was between 1-4. In sensitivity analysis we
- 161 explored changing our default value of 1 to 4 for (a) everyone, (b) males only and (c)
- 162 children only (< 20yos).

### 164 Results

165

- 166 Prescription data
- Over the 9-year period April 2015 to December 2023, 249, 578, 795 prescriptions of 167 168 antibiotics were given in England. For the complete years (2016-2023), the average was 169 0.48 (range of 0.43, 0.52) prescriptions per person per year. The most frequently 170 prescribed drugs were amoxicillin, nitrofurantoin and Flucloxacillin sodium(Table 1). 171 63% (63%, 64%) of drugs were prescribed to females, with 0.60 (0.54, 0.65) per person 172 per year versus 0.36 (0.31, 0.40) in men. 13% (10%, 15%) of prescriptions were given to 173 those <16yo, and 35% (33%, 37%) to those over 65yo. The highest overall prescription 174 rate in both sexes was in the 86yo+ band (Appendix 1 section 5). COVID-19 mostly 175 affected prescribing in those aged < 16yos (Appendix 1 section 5), mostly returning to 176 pre-COVID-19 levels in the Spring of 2021.

177

The top 20 prescribed antibiotics, totalling 98% of prescriptions, (Table 1) had annual 178 179 prescription totals varying from 74,159 to over 6.5 million prescriptions, with most being 180 prescribed more commonly to females (17/20) and most often in December (9/20) or 181 January (5/20). Those prescribed more to men were ciprofloxacin, co-trimoxazole and 182 rifamixin. Just over half of the top 20 prescribed antibiotics had fewer prescriptions in 183 2023 than 2016 (11/20), with 61% of antibiotic having at least a 10% reduction in 184 prescriptions between 2019 and 2023, although some had sex-based time variation 185 (e.g. ofloxacin, Fig 1B). Most of the top 20 antibiotics (15/20) had the highest rates in older ages (>55yos) in 2023. 186

		Mean	% to	Тор		Total in		Top age band (2023)	
Antibiotic	Total	(annual)	females	month	2016	2019	2023	Females	Males
Amoxicillin	53,415,335	6,676,917	58	12	8,130,012	6,673,263	7,311,226	0-1,2-5,86+	0-1,2-5,86+
Nitrofurantoin	27,953,870	3,494,234	83	10	2,358,297	3,740,424	3,808,622	76-80,81-85,86+	76-80,81-85,86+
Flucloxacillin sodium	26,940,364	3,367,546	55	7	3,488,057	3,270,904	3,384,802	76-80,81-85,86+	76-80,81-85,86+
Doxycycline hyclate	22,868,632	2,858,579	60	12	2,415,657	2,772,514	3,804,564	76-80,81-85,86+	76-80,81-85,86+
Penicillin V	15,557,160	1,944,645	59	12	1,892,172	1,841,679	2,447,555	2-5,6-10,16-20,	0-1,2-5,6-10
Trimethoprim	14,439,590	1,804,949	75	1	3,087,875	1,488,922	1,428,569	76-80,81-85,86+	76-80,81-85,86+
Clarithromycin	14,417,677	1,802,210	63	1	2,077,261	1,845,315	1,743,846	76-80,81-85,86+	76-80,81-85,86+
Co-amoxiclav	9,181,476	1,147,684	60	1	1,304,696	1,094,885	1,092,620	76-80,81-85,86+	76-80,81-85,86+
Lymecycline	7,938,074	992,259	58	3	1,054,631	1,032,182	861,423	11-15,16-20,21-25	11-15,16-20,21-25
Cefalexin	5,910,292	738,786	80	12	748,696	668,339	816,579	76-80,81-85,86+	76-80,81-85,86+
Azithromycin	5,877,890	734,736	57	12	612,414	748,885	805,700	71-75,76-80,81-85	76-80,81-85,86+
Metronidazole	4,156,192	519,524	78	3	599,382	520,332	474,629	21-25,26-30,31-35	76-80,81-85,86+
Ciprofloxacin	3,564,433	445,554	48	1	532,816	445,243	355,804	76-80,81-85,86+	76-80,81-85,86+
Erythromycin	3,397,046	424,631	66	1	709,522	394,861	286,163	76-80,81-85,86+	76-80,81-85,86+
Oxytetracycline	2,432,724	304,090	51	3	463,514	310,851	178,452	61-65,66-70,76-80	71-75,76-80,81-85
Piv. hydrochloride	1,790,378	223,797	79	10	108,361	223,030	301,447	76-80,81-85,86+	76-80,81-85,86+
Ery. ethylsuccinate	1,576,325	197,041	50	12	341,227	171,870	164,552	0-1,2-5,6-10	0-1,2-5,6-10
Co-trimoxazole	1,417,031	177,129	44	12	129,051	173,722	228,051	66-70,76-80,81-85	76-80,81-85,86+
Meth. Hippurate	1,060,060	132,508	80	12	40,789	82,081	319,013	76-80,81-85,86+	76-80,81-85,86+
Rifaximin	593,273	74,159	41	12	33,589	71,036	109,205	56-60,61-65,66-70	56-60,61-65,66-7

188 Table 1: Summary data on number of prescriptions for the 20 most prescribed antibiotics (see Appendix 1 section 6 for all antibiotics) across the complete years of the data (2016-


189 2023) unless otherwise indicated. Red shading indicates more prescriptions are to females and "Top" month is the month with the most prescriptions of this antibiotic (1 = January),

190 when summing across the whole dataset. "Top age band (2023)" is the age band in 2023 with the highest prescription rate per 100k. Light green shading indicates relatively more

191 prescriptions to younger individuals vs top age bands all being 55yo or more (Ery. is Erythromycin. Co-amoxiclav is amoxicillin and clavulanic acid, Co-trimoxazole is trimethoprim

192 and sulfamethoxazole. Piv. = Pivmecillinam. Meth. = Methenamine.)

- 193 Twenty-eight antibiotics (38%) show an annual seasonal pattern (Fig 1A, Appendix 2) in
- 194 prescriptions (pre-COVID-19), defined as having at least two months where
- 195 prescriptions were 20% higher than the average number of prescriptions, averaged over
- 196 years. These seasonal antibiotics, all had a decrease in prescriptions during the COVID-
- 197 19- period, followed by a spike in late 2022 (Appendix 2) correlating with a
- 198 Streptococcus A outbreak and amoxicillin shortage<sup>35</sup>.
- 199
- 200 For most age bands higher levels of prescription in females compared to males (Fig 1C),
- 201 were observed (84% / 54% / 24% of antibiotics had more prescriptions to females in at
- least 50% / 75% / 90% of age bands respectively). Notable exceptions with higher
- 203 prescriptions to males are quinolones, isoniazid and minocycline hydrochloride. For
- some ages the sex that receives the most prescriptions changes with age (e.g.
- 205 colistimethate sodium, azithromycin and rifampicin have higher prescriptions in males
- 206 in children, higher prescription rates in females in adults (Fig 1C)).
- 207




209 Figure 1: Variation in antibiotic prescribing by age and sex with examples and overall comparison A/B). Example 210 prescription rate per 100'000 population for clarithromycin and ofloxacin respectively. Colours indicate age bands, 211 facets indicate sex. Grey shading indicates years of COVID-19 interventions. See Appendix 2 for all antibiotics. C) 212 Relative prescription rate by sex for prescribed medicines in 2023. Colours represents the log of the ratio, with blue 213 indicating higher prescriptions in women, and green indicating higher prescriptions in men. Drugs are ordered by BNF 214 classification, where the acronyms are: Clindamycin and lincomycin = "C&L", Cephalosporins and other beta-215 lactams = "Ceph's", Antileprotic drugs = "Lep", Metronidazole, tinidazole and ornidazole = "MTO", Sulphonamides and 216 trimethoprim= "S&T", Antituberculosis drugs = "TB", Urinary-tract infections = "UTIs".

217

#### 218 Antibiotic usage metric

- We created an updated comparison metric (UCM), with smaller age bands than STAR-219
- 220 PU (Figure 2B). This resulted in more extreme values across age bands, ranging from
- 221 0.19 to 2 in our UCM, compared to a range of 0.2 – 1.3 in the 2013 STAR-PU with
- particularly higher values in older males (Figure 2A vs B). Values by BNF drug value 222
- varied considerably by age and sex ("UCM-family", Appendix 1 section 7). 223

- 225 The new-UCM ranking of ICBs (first column Fig 2C, lines in Fig 2D), changed
- substantially when applying the UCM-family (Fig 2C, points in Figure 2D). For example,
- 227 ICB QRL ranks as a high prescriber with the new-UCM (6<sup>th</sup> overall, Fig 2C, red in
- Fig2C&D) but a low prescriber of quinolones (38<sup>th</sup> overall, Appendix 1 section 9). The
- range in UCM-family ranking decreased with more prescriptions (Fig 2D).
- 230



232 Figure 2: A)2013 STAR-PU values using England data. B) Updated Comparison Metric (UCM) using 2023 English data 233 and more disaggregated age bands. Blue = high value, green = low value, centred around the baseline: females, 66-70 234 (white). C) Ranking of UCMs across English ICBs, grouped by colour into quarters: rank 1-10 (1), 11-20 (2), 21-30 (3) 235 and 30-42 (4). The "Overall" column shows the ranking of ICBs using our UCM, and the other columns by UCM-family. 236 Acronyms: Clindamycin and lincomycin = "C&L", Cephalosporins and other beta-lactams = "Ceph's", Antileprotic 237 drugs = "Lep", Metronidazole, tinidazole and ornidazole = "MTO", Sulphonamides and trimethoprim="S&T", 238 Antituberculosis drugs = "TB", Urinary-tract infections = "UTIs". D) Normalised prescriptions per English ICB and 239 antibiotic (facet) for overall UCM (lines, same on each facet) and UCM-families (dots). In C) and D) the same three 240 ICBs are highlighted with colour (blue, yellow and pink). n indicates the total number of prescriptions across all ICBs.


241

231

242 Antibiotic consumption targets

243 The WHO 60% "Access" prescribing target has been reached in England: 84% of primary 244 care prescriptions were "Access" in 2023. However, the more ambitious 80% level is not 245 being met in males ages 11-20, largely driven by a spike in prescriptions for lymecycline 246 (Figure 3B), commonly prescribed for Acne<sup>36</sup>. The main Reserve drug prescribed by GPs 247 in 2023 was colisitimethate sodium, which must be given by injection or as a nebuliser 248 as it is not given orally <sup>37</sup>, likely under the direction of tertiary care, particularly for Cystic 249 Fibrosis patients <sup>38,39</sup>. The percentage of antibiotics that were "Access" varied across ICBs by between 5.3% (females, aged 6-10) to 13.4% (males, aged 16-20) (Appendix 1 250

251 Section 10).




252 253

Figure 3: A) Percentage of total prescriptions in each of the AWaRe categories (row), by age band, sex (column) and
year (colour). Dashed horizontal lines represent targets of 60% and 80% in the Access category, and dotted vertical
lines are included for comparison across graphs. Note the difference in y-axis ranges. B) Total prescriptions in 2023 by
AWaRe categories (row), age band and sex (columns). Key contributing drugs are highlighted by colour and vertical
dotted lines are included for comparison across graphs.

259 Influenza vaccination

260 Comparing the relative rate of prescriptions commonly given for (suspected) RTIs before 261 and after influenza vaccination programmes (Figure 4A) shows no clear impact. For 262 example, compared to ages 15-50, RTI relative prescription rates declined by just under 5% in age band 6-10 following introduction of vaccination in 7-8yos (Figure 4A&B). 263 264 However, in this same period the prescriptions in age bands 0-1 decreased by over 10%. 265 There was an increase in relative prescriptions in all ages except older adults when 266 vaccination was introduced in 4-5yos & 8-9yos. Vaccination of 50-65yos would likely 267 have the largest impact (more people), but is hard to interpret, as this occurred during 268 the COVID-19 years. No decrease in prescriptions in this age band compared to the

269 other age bands was identified (Fig 4A).



- 270
- 271
- 272 Figure 4: A) Age band specific prescription rates of RTI antibiotics (penicillins, cephalosporins and other beta-
- 273 lactams) relative to the rate in age band 15-50. Amoxicillin was excluded (see methods). The influenza season was
- 274 defined as 1<sup>st</sup> of October to 30<sup>th</sup> March inclusive. Vertical lines indicate the year the introduction of vaccination in the
- 275 labelled age band, and the COVID-19 years are shaded grey. B) Proportional change in the number of RTI
- prescriptions (excluding amoxicillin) from the influenza season of the previous year, by age band. Vertical lines

indicate the introduction of vaccinations in the named age bands C) Prescription rate of beta-lactam antibiotics (top
row) and proportion of BSI due to resistant S. aureus (over all S. aureus BSI) for similar age bands (columns).

279

- 280 Impact on antimicrobial resistance (AMR)
- 281 There was a lack of a clear link between prescribing and resistance rates by age and sex
- for S. aureus (Figure 4C). All age bands except ages 0-1 see higher prescriptions of beta-
- 283 lactam antibiotics (those to which MRSA are resistant) in females, yet the proportion of
- BSIs due to MRSA is higher in males 45yo and over, and varies over time in 1-44yo. As
- 285 opposed to prescriptions, a higher proportion of BSIs were due to MRSA in females in
- age band <1 over time.
- 287
- 288 Sensitivity analyses

The majority of age bands across drugs show higher levels of prescription in females
compared to males in all sensitivity analysis. When the hidden low prescription
numbers (\*s) were all set to the maximum possible value (4 instead of 1, equating to
0.13% instead of 0.033% of all prescriptions), 85% / 55% / 27% of antibiotics had more
prescriptions to females in at least 50% / 75% / 90% of age bands respectively. The
sensitivity analysis with the higher value (4) in males only or children only had highly
similar levels of 78% / 55% /18% and 85% / 55% / 24% respectively (Appendix 1 section)

296 7).

### 297 Discussion

298

We report here, for the first time, national data on all antibiotic prescriptions in primary care in England disaggregated by both 5yr age bands and sex. This unprecedented level of detail highlights huge variation and will be vital in bringing a more nuanced approach to AMR control.

303

304 Whilst most antibiotics (15/20 of most prescribed antibiotics) had higher prescription 305 rates in older ages (55yo+), a substantial proportion had higher prescription rates in 306 children or younger adults. Matching previous reporting <sup>7-10</sup>, women were prescribed 307 more antibiotics, but this pattern was not uniform across age bands and the patterns 308 seen would have been hidden if using only three age groupings. Higher prescribing in 309 women is likely linked to both infection syndrome variation and to behavioural 310 differences in consultation rates <sup>8,40–43</sup>. We saw clear syndrome-linked prescribing: 311 higher levels of UTI prescribing (nitrofurantoin and trimethoprim) in women and higher 312 levels of prostate or gonorrhoea infection linked prescribing (ofloxacin) in men. 313 Quantifying this age and sex variation provides a baseline for intervention targeting and 314 may help assess prescription appropriateness. 315 316 Most antibiotics (~60%) did not have a seasonal pattern of exposure. Those that did had

a lower prescribing rate during COVID-19, likely reflecting that antibiotics prescribed
seasonally are given for infections that are dependent on seasonal changes in
transmission (schools / time indoors), or linked to other infections (e.g. respiratory
viruses <sup>44,45</sup>). Supporting this theory is the rapid increase in prescribing in late 2022

321 which coincided with a Streptococcus A outbreak and a wide increase in prevalence of respiratory virus infections linked to "re-opening"<sup>46</sup>. How this could drive seasonality in 322 323 AMR needs untangling. Other studies have found a similar decrease in prescribing during COVID-19 in primary care in sub-national data in the UK<sup>47</sup><sup>48</sup>, mostly driven by 324 325 prescribing in children. 326 327 These data allow for more subtle analysis of prescribing outliers. We found that STAR-328 PU likely underestimates prescribing to older adults, especially males and that a metric 329 split by antibiotic family would better identify outliers. This analysis strengthens the 330 case for updated STAR-PUs<sup>49</sup>. 331 332 England is exceeding the WHO "60% Access" targets for antibiotic use, and likely has 333 been since 2018, like other European settings<sup>50</sup>. However, this data shows the utility of knowing the variation by detailed age bands and sex: males aged 11-20 had less than 334 335 60% Access in 2015, rising to 70% in 2023 due to an increase in prescribing of the watch 336 antibiotic lymecycline, likely for acne<sup>36</sup>. Whilst also spiking in females, due to the higher overall prescribing in women, their proportion Access remains above 70%. 337 338

Interventions to reduce antibiotic prescribing, including the Quality Premium, appear to
be working in general in England, with most antibiotics (61%) having at least a 10%
reduction in prescriptions between 2019 and 2023 <sup>51,52</sup>. Disaggregating by age and sex
reveals subgroups where changes in prescribing practice could be further targeted e.g.
ofloxacin use has increased in men since 2016, potentially linked to rises in gonorrhoea
Interestingly, a large reduction in prescriptions is not evidently driven by more ages

345	being eligible for influenza vaccination: despite roughly 50% vaccine coverage we saw
346	little prescription reduction in that 'flu season in the age group vaccinated nor in linked
347	age groups known to benefit from 'flu vaccination of children (e.g. 65+ age band) $^{54,55}$ .
348	These results are lower than those previously reported (e.g. 29% reduction in antibiotic
349	prescribing in one systematic review <sup>22</sup> ) potentially due to our grouping antibiotics
350	together, using wider age bands (to match vaccine targets) and not considering
351	influenzas complexity (e.g. strain variation). The impact of influenza vaccinations may
352	also be higher in other non-UK settings.
353	

354 When considering AMR selection, we found no obvious link between the age and sex 355 disaggregated exposures of beta-lactam antibiotics in primary care and higher MRSA 356 prevalence in bloodstream infections (BSIs) in England. However, MRSA is often a 357 hospital-associated pathogen <sup>56</sup>, and BSIs are usually treated in hospitals, hence a lack 358 of a strong link might have been expected but not no link. More broadly, we clearly see that women receive more antibiotics in primary care, which is at odds with higher male 359 360 resistance rates in our previous research in BSIs across Europe<sup>25</sup> and available UK 361 data<sup>33</sup>. Such patterns point to unexplained complexity in the pathways to resistance 362 acquisition and potential intervention targets such as increased age or even sex-based 363 prescribing recommendations. Untangling the link from ABU to AMR will require further 364 age and sex disaggregated data but also information on other covariables such as patient ethnicity, deprivation level and co-morbidities <sup>18,57</sup>. 365

366

Whilst the data used here is unparalleled in its detail and completeness, more patientdata was available at later time points (a total of 3.3% of prescriptions were excluded),

369 leading us to focus on the more complete 2023 data and we had to use sensitivity 370 analyses to explore the hidden low numbers of prescriptions. Our data improves upon 371 previous studies which have banded either patient age (in 10+ age bands), not considered disaggregation by sex or only focused on a subset of patient diagnoses 7-9. 372 373 Moreover, much work in the UK is not all national data, using either only a subset of GPs 374 <sup>8,9,57,58</sup> which although designed to be representative, may miss subtle geographical variation or incomplete market coverage (e.g. IQVIA has 89% market coverage in the UK 375 <sup>50</sup>). However, here we only had access to prescription data, with no measure of the 376 377 propensity to take the prescribed medicine and whether this varies by age, sex, time or 378 drug, no linked diagnosis or reason for prescribing, and only "Items", rather than a more specific quantification, such as daily defined doses (DDDs) or grams <sup>59</sup>. This is 379 380 important as dose and duration of exposure is potentially relevant to the development 381 of resistance 60-62. 382 The generalisability of this analysis to other locations is likely low (except in related 383 384 geographies e.g. Wales, Scotland etc.), as the results may not be applicable to 385 countries with different prescribing guidelines and healthcare systems (e.g. US 386 insurance-based prescribing <sup>63</sup>, or over-the-counter availability in LMICs <sup>64</sup>). However, 387 many of the underlying infection syndromes and behaviour patterns may exist and 388 hence our findings add to the increasing evidence that we need disaggregated data by

age and sex to optimally intervene against AMR.

390

Our analysis highlights the possibilities of using FOI requests in research. Future
researchers could request additional UK data, e.g. at the GP level over larger time

393	periods to avoid the issue of small numbers, as well as exploring requests for further
394	(ideally linked) data that could help answer questions on health inequality such as
395	socio-economic status and secondary health care infrastructure $^{65}$ .
396	
397	Overall, by showing wide antibiotic prescription variation across age and sex this
398	research has demonstrated the need for a nuanced approach when exploring and
399	understanding trends in ABU. Understanding how this affects the global public health
400	problem that is AMR can only be done with matched age and sex disaggregated AMR
401	data otherwise the impact of ABU targets, ageing populations and future interventions
402	will be very hard to determine.
403	
404	
405	Acknowledgments
406	We would like to thank Yasmin Gant for supporting our understanding of reasons for
407	antibiotic prescriptions, and Stephanie Evans for providing feedback on the manuscript.
408	
409	Funding
410	GMK and NRW were supported by the Medical Research Council UK,
411	https://www.ukri.org/opportunity/career-development-award/ (MR/W026643/1). The
412	funders had no role in study design, data collection and analysis, decision to publish, or
413	preparation of the manuscript
414	
415	Transparency declarations
416	No conflicts to declare.

## 417 References

- 419 1. WHO. Indicator Metadata Registry Details. https://www.who.int/data/gho/indicator-
- 420 metadata-registry/imr-details/5767.
- 421 2. WHO. AWaRe. https://adoptaware.org/ (2021).
- 422 3. Sharland, M. et al. The WHO AWaRe Antibiotic Book: providing guidance on optimal
- 423 use and informing policy. *Lancet Infect. Dis.* **22**, 1528–1530 (2022).
- 424 4. Mendelson, M. et al. Ensuring progress on sustainable access to effective
- 425 antibiotics at the 2024 UN General Assembly: a target-based approach. *The Lancet*
- 426 **403**, 2551–2564 (2024).
- 427 5. NHS England. Community pharmacy quality scheme 2020-22: findings and
- 428 recommendations from the antimicrobial stewardship initiatives.
- 429 https://www.england.nhs.uk/long-read/community-pharmacy-quality-scheme-
- 430 2020-22-findings-and-recommendations-from-the-antimicrobial-stewardship-
- 431 initiatives/ (2023).
- 432 6. Sijbom, M., Büchner, F. L., Saadah, N. H., Numans, M. E. & De Boer, M. G. J. Trends in
- 433 antibiotic selection pressure generated in primary care and their association with
- 434 sentinel antimicrobial resistance patterns in Europe. *J. Antimicrob. Chemother.* 78,
  435 1245–1252 (2023).
- 436 7. Schröder, W. et al. Gender differences in antibiotic prescribing in the community: a
- 437 systematic review and meta-analysis. J. Antimicrob. Chemother. **71**, 1800–1806
- 438 (2016).

- 439 8. Smith, D. R. M., Dolk, F. C. K., Smieszek, T., Robotham, J. V. & Pouwels, K. B.
- 440 Understanding the gender gap in antibiotic prescribing: a cross-sectional analysis of
- 441 English primary care. *BMJ Open* **8**, e020203 (2018).
- 442 9. Majeed, A. & Moser, K. Age- and sex-specific antibiotic prescribing patterns in
- 443 general practice in England and Wales in 1996. Br. J. Gen. Pract. 49, 735–736 (1999).
- 444 10. Hayward, G. N., Fisher, R. F. R., Spence, G. T. & Lasserson, D. S. Increase in
- 445 antibiotic prescriptions in out-of-hours primary care in contrast to in-hours primary
- 446 care prescriptions: service evaluation in a population of 600000 patients. J.
- 447 Antimicrob. Chemother. **71**, 2612–2619 (2016).
- 448 11. Dolk, F. C. K., Pouwels, K. B., Smith, D. R. M., Robotham, J. V. & Smieszek, T.
- 449 Antibiotics in primary care in England: which antibiotics are prescribed and for
- 450 which conditions? J. Antimicrob. Chemother. **73**, ii2–ii10 (2018).
- 451 12. Dias, S. P., Brouwer, M. C. & van de Beek, D. Sex and Gender Differences in Bacterial
- 452 Infections. *Infect. Immun.* **90**, e0028322 (2022).
- 453 13. Foxman, B. The epidemiology of urinary tract infection. *Nat. Rev. Urol.* 7, 653–660
  454 (2010).
- 455 14. Mor, A. *et al.* Antibiotic use varies substantially among adults: a cross-national
- 456 study from five European Countries in the ARITMO project. *Infection* **43**, 453–472
- 457 (2015).
- 458 15. European Centre for Disease Prevention and Control. Antimicrobial Consumption in
  459 the EU/EEA (ESAC-Net) Annual Epidemiological Report for 2021.
- 460 https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-
- 461 consumption-europe-2021 (2022).

- 462 16. Browne, A. J. et al. Global antibiotic consumption and usage in humans, 2000–18: a
- 463 spatial modelling study. *Lancet Planet. Health* **5**, e893–e904 (2021).
- 464 17. Motta, M., Wilcock, M. & Heald, A. Using defined daily doses to review antibiotic
- 465 prescribing. *Prescriber* **32**, 19–25 (2021).
- 466 18. Hope, E. C. *et al.* Identifying English Practices that Are High Antibiotic Prescribers
- 467 Accounting for Comorbidities and Other Legitimate Medical Reasons for Variation.
- 468 *EClinicalMedicine* **6**, 36–41 (2018).
- 469 19. Lloyd, D. C., Harris, C. M. & Roberts, D. J. Specific therapeutic group age-sex related
- 470 prescribing units (STAR-PUs): weightings for analysing general practices' prescribing
- 471 in England. *BMJ* **311**, 991–994 (1995).
- 472 20. Krishnakumar, J. & Tsopra, R. What rationale do GPs use to choose a particular
- 473 antibiotic for a specific clinical situation? *BMC Fam. Pract.* **20**, 178 (2019).
- 474 21. McDermott, D. Antimicrobial Prescribing Guidance NICE & PHE Update. NECS
- 475 *Medicines Optimisation* https://medicines.necsu.nhs.uk/antimicrobial-prescribing-
- 476 guidance-nice-phe-update/ (2018).
- 477 22. van Heuvel, L., Paget, J., Dückers, M. & Caini, S. The impact of influenza and
- 478 pneumococcal vaccination on antibiotic use: an updated systematic review and
- 479 meta-analysis. *Antimicrob. Resist. Infect. Control* **12**, 70 (2023).
- 480 23. Barchitta, M., Maugeri, A., Vinci, R. & Agodi, A. The Inverse Relationship between
- 481 Influenza Vaccination and Antimicrobial Resistance: An Ecological Analysis of
- 482 Italian Data. *Vaccines* **10**, 554 (2022).
- 483 24. Tadesse, B. T. et al. Vaccination to Reduce Antimicrobial Resistance Burden—Data
- 484 Gaps and Future Research. *Clin. Infect. Dis.* **77**, S597–S607 (2023).

- 485 25. Waterlow, N. R., Cooper, B. S., Robotham, J. V. & Knight, G. M. Antimicrobial
- 486 resistance prevalence in bloodstream infection in 29 European countries by age and
- 487 sex: An observational study. *PLOS Med.* **21**, e1004301 (2024).
- 488 26. NHSBSA. FOI-01671 Open Data Portal BETA.
- 489 https://opendata.nhsbsa.net/dataset/foi-01671 (2024).
- 490 27. Open Prescribing. BNF 5.1: Antibacterial drugs | OpenPrescribing.
- 491 https://openprescribing.net/bnf/0501/ (2024).
- 492 28. ONS. Estimates of the population for the UK, England, Wales, Scotland, and
- 493 Northern Ireland Office for National Statistics.
- 494 https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/
- 495 populationestimates/datasets/populationestimatesforukenglandandwalesscotland
- 496 and northernireland (2024).
- 497 29. ONS. Health geographies population estimates (Accredited official statistics) -
- 498 Office for National Statistics.
- 499 https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/
- 500 populationestimates/datasets/clinicalcommissioninggroupmidyearpopulationesti
- 501 mates (2024).
- 502 30. WHO. AWaRe classification of antibiotics for evaluation and monitoring of use,
- 503 2023. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.04
- 504 (2023).
- 505 31. Vaccine uptake guidance and the latest coverage data. *GOV.UK*
- 506 https://www.gov.uk/government/collections/vaccine-uptake (2024).
- 507 32. NICE. Amoxicillin | Drugs | BNF content published by NICE.
- 508 https://bnf.nice.org.uk/drugs/amoxicillin/ (2024).

- 509 33. MRSA, MSSA and Gram-negative bacteraemia and CDI: annual report. GOV.UK
- 510 https://www.gov.uk/government/statistics/mrsa-mssa-and-e-coli-bacteraemia-
- 511 and-c-difficile-infection-annual-epidemiological-commentary (2024).
- 512 34. R Core Team. R: A language and environment for statistical computing. R
- 513 Foundation for Statistical Computing, Vienna, Austria. (2018).
- 514 35. Gilchrist, K. Antibiotics prices surge in UK amid Strep A outbreak, leaving drugstores
- 515 'footing the bill'. CNBC https://www.cnbc.com/2022/12/13/strep-a-antibiotics-
- 516 prices-shortages-hit-drugstores-amid-uk-outbreak.html (2022).
- 517 36. Lymecycline | Drugs | BNF content published by NICE.
- 518 https://bnf.nice.org.uk/drugs/lymecycline/ (2024).
- 519 37. Colistimethate sodium | Drugs | BNF content published by NICE.
- 520 https://bnf.nice.org.uk/drugs/colistimethate-sodium/ (2024).
- 521 38. NHS. Inhaled Therapy for Adults and Children with Cystic Fibrosis.
- 522 https://www.england.nhs.uk/wp-content/uploads/2018/07/Inhaled-therapy-for-
- 523 adults-and-children-with-cystic-fibrosis.pdf (2024).
- 524 39. NICE. Colistimethate sodium and tobramycin dry powders for inhalation for treating
- 525 pseudomonas lung infection in cystic fibrosis | Guidance | NICE.
- 526 https://www.nice.org.uk/guidance/ta276/chapter/2-Clinical-need-and-practice
- 527 (2013).
- 40. Bagger, K., Nielsen, A. B. S., Siersma, V. & Bjerrum, L. Inappropriate antibiotic
- 529 prescribing and demand for antibiotics in patients with upper respiratory tract
- 530 infections is hardly different in female versus male patients as seen in primary care.
- 531 *Eur. J. Gen. Pract.* **21**, 118–123 (2015).

- 41. Briscoe, M. E. Why do people go to the doctor? Sex differences in the correlates of
- 533 GP consultation. Soc. Sci. Med. 1982 **25**, 507–513 (1987).
- 42. Wang, Y., Hunt, K., Nazareth, I., Freemantle, N. & Petersen, I. Do men consult less
- 535 than women? An analysis of routinely collected UK general practice data. *BMJ Open*
- 536 **3**, e003320 (2013).
- 43. Harvey, E. J., De Brún, C., Casale, E., Finistrella, V. & Ashiru-Oredope, D. Influence of
- 538 factors commonly known to be associated with health inequalities on antibiotic use
- 539 in high-income countries: a systematic scoping review. J. Antimicrob. Chemother.
- 540 **78**, 861–870 (2023).
- 541 44. Smith, A. M. & McCullers, J. A. Secondary Bacterial Infections in Influenza Virus
- 542 Infection Pathogenesis. *Influenza Pathog. Control Vol. I* **385**, 327–356 (2014).
- 543 45. Joseph, C., Togawa, Y. & Shindo, N. Bacterial and viral infections associated with
  544 influenza. *Influenza Other Respir. Viruses* 7, 105–113 (2013).
- 545 46. Feinmann, J. Analysis reveals global post-covid surge in infectious diseases. *BMJ*546 385, q1348 (2024).
- 547 47. Zhu, N. *et al.* Investigating the impact of COVID-19 on primary care antibiotic
- 548 prescribing in North West London across two epidemic waves. *Clin. Microbiol.*
- 549 Infect. **27**, 762–768 (2021).
- 48. Rezel-Potts, E., L'Esperance, V. & Gulliford, M. C. Antimicrobial stewardship in the
- 551 UK during the COVID-19 pandemic: a population-based cohort study and
- interrupted time-series analysis. *Br. J. Gen. Pract.* **71**, e331–e338 (2021).
- 49. STAR-PUs should we still be using them? | Bennett Institute for Applied Data
- 554 Science. https://www.bennett.ox.ac.uk/blog/2024/02/star-pus-should-we-still-be-
- 555 using-them/ (2024).

- 556 50. Simmons, B. et al. Progress towards antibiotic use targets in eight high-income
- 557 countries. *Bull. World Health Organ.* **99**, 550–561 (2021).
- 558 51. Bou-Antoun, S. et al. Age-related decline in antibiotic prescribing for uncomplicated
- respiratory tract infections in primary care in England following the introduction of a
- 560 national financial incentive (the Quality Premium) for health commissioners to
- 561 reduce use of antibiotics in the community: an interrupted time series analysis. J.
- 562 *Antimicrob. Chemother.* **73**, (2018).
- 563 52. Balinskaite, V., Ap, J., A, H. & P, A. The Impact of a National Antimicrobial
- 564 Stewardship Program on Antibiotic Prescribing in Primary Care: An Interrupted Time
- 565 Series Analysis. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **69**, (2019).
- 566 53. Sexually transmitted infections (STIs): annual data. GOV.UK
- 567 https://www.gov.uk/government/statistics/sexually-transmitted-infections-stis-
- 568 annual-data-tables (2024).
- 569 54. Baguelin, M. et al. Assessing Optimal Target Populations for Influenza Vaccination
- 570 Programmes: An Evidence Synthesis and Modelling Study. *PLoS Med.* **10**, (2013).
- 571 55. Schmidt-Ott, R. *et al*. Assessing direct and indirect effects of pediatric influenza
- 572 vaccination in Germany by individual-based simulations. *Hum. Vaccines*
- 573 *Immunother.* **16**, 836–845 (2019).
- 574 56. NHS England. Healthcare associated infections.
- 575 https://www.england.nhs.uk/patient-safety/healthcare-associated-infections/576 (2024).
- 577 57. Shallcross, L., Beckley, N., Rait, G., Hayward, A. & Petersen, I. Antibiotic prescribing
- 578 frequency amongst patients in primary care: a cohort study using electronic health
- 579 records. J. Antimicrob. Chemother. **72**, 1818–1824 (2017).

- 580 58. Palin, V. *et al.* Antibiotic prescribing for common infections in UK general practice:
- 581 variability and drivers. J. Antimicrob. Chemother. **74**, 2440–2450 (2019).
- 582 59. Ways for prescribing to be measured. *The Pharmaceutical Journal*
- 583 https://pharmaceutical-journal.com/article/ld/ways-for-prescribing-to-be-
- 584 measured (2004).
- 60. Roberts, J. A., Kruger, P., Paterson, D. L. & Lipman, J. Antibiotic resistance--what's
- 586 dosing got to do with it? *Crit. Care Med.* **36**, 2433–2440 (2008).
- 587 61. Teshome, B. F., Vouri, S. M., Hampton, N., Kollef, M. H. & Micek, S. T. Duration of
- 588 Exposure to Antipseudomonal β-Lactam Antibiotics in the Critically III and
- 589 Development of New Resistance. *Pharmacotherapy* **39**, 261–270 (2019).
- 590 62. Day, T. & Read, A. F. Does High-Dose Antimicrobial Chemotherapy Prevent the
- 591 Evolution of Resistance? *PLoS Comput. Biol.* **12**, e1004689 (2016).
- 592 63. Olesen, S. W. *et al.* The distribution of antibiotic use and its association with
- 593 antibiotic resistance. *eLife* **7**, (2018).
- 64. Kanan, M. *et al.* Empowering Low- and Middle-Income Countries to Combat AMR by
- 595 Minimal Use of Antibiotics: A Way Forward. *Antibiotics* **12**, 1504 (2023).
- 596 65. The Kings fund. Health inequalities in a nutshell. *The King's Fund*
- 597 https://www.kingsfund.org.uk/insight-and-analysis/data-and-charts/health-
- 598 inequalities-nutshell (2024).